BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21111964)

  • 21. Treatment of metastatic melanoma: an overview.
    Bhatia S; Tykodi SS; Thompson JA
    Oncology (Williston Park); 2009 May; 23(6):488-96. PubMed ID: 19544689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy: Vaccine trials in melanoma -- time for reflection.
    Eggermont AM
    Nat Rev Clin Oncol; 2009 May; 6(5):256-8. PubMed ID: 19390551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Melanoma: Cellular and vaccinal immunotherapy].
    Dréno B; Khammari A; Knol AC; Labarrière N
    Bull Acad Natl Med; 2014 Feb; 198(2):309-19; discussion 319. PubMed ID: 26263706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.
    Oosterhoff D; Sluijter BJ; Hangalapura BN; de Gruijl TD
    Curr Top Microbiol Immunol; 2012; 351():181-220. PubMed ID: 21681685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
    Hellmann MD; Snyder A
    Immunity; 2017 Aug; 47(2):221-223. PubMed ID: 28813655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach.
    Agarwala SS; O'Day SJ
    Cancer Treat Rev; 2011 Apr; 37(2):133-42. PubMed ID: 20638184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review: dendritic cell immunotherapy for melanoma.
    Hadzantonis M; O'Neill H
    Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanoma: is immunotherapy of benefit?
    Faries MB; Morton DL
    Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
    [No Abstract]   [Full Text] [Related]  

  • 29. Melanoma vaccines: developments over the past 10 years.
    Klein O; Schmidt C; Knights A; Davis ID; Chen W; Cebon J
    Expert Rev Vaccines; 2011 Jun; 10(6):853-73. PubMed ID: 21692705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies.
    Weber JS
    Melanoma Res; 2006 Oct; 16(5):379-83. PubMed ID: 17013086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for melanoma.
    Kim CJ; Dessureault S; Gabrilovich D; Reintgen DS; Slingluff CL
    Cancer Control; 2002; 9(1):22-30. PubMed ID: 11907463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies to overcome obstacles to successful immunotherapy of melanoma.
    Pandolfi F; Cianci R; Lolli S; Dunn IS; Newton EE; Haggerty TJ; Boyle LA; Kurnick JT
    Int J Immunopathol Pharmacol; 2008; 21(3):493-500. PubMed ID: 18831916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of malignant melanoma.
    Goldstein BG; Goldstein AO
    Am Fam Physician; 2001 Apr; 63(7):1359-68, 1374. PubMed ID: 11310650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances and hurdles in melanoma immunotherapy.
    Jandus C; Speiser D; Romero P
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):711-23. PubMed ID: 19735459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma.
    Geng H; Zhang GM; Xiao H; Yuan Y; Li D; Zhang H; Qiu H; He YF; Feng ZH
    Int J Cancer; 2006 Jun; 118(11):2657-64. PubMed ID: 16425224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment of melanoma with an emphasis on immunotherapeutic strategies.
    Jack A; Boyes C; Aydin N; Alam K; Wallack M
    Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.